Scarica l'app Stockscreener
2.43
13.02%
0.28
Precedente Chiudi:
$2.15
Aprire:
$2.17
Volume 24 ore:
339.09K
Relative Volume:
0.50
Capitalizzazione di mercato:
$61.35M
Reddito:
-
Utile/perdita netta:
$-21.24M
Rapporto P/E:
-2.9001
EPS:
-0.8379
Flusso di cassa netto:
$-22.47M
1 W Prestazione:
+22.73%
1M Prestazione:
+31.00%
6M Prestazione:
-34.68%
1 anno Prestazione:
-78.53%
Intervallo 1D:
$2.17
$2.48
Intervallo di 1 settimana:
$1.99
$2.48
Portata 52W:
$1.14
$11.20
Skye Bioscience Inc Stock (SKYE) Company Profile
Nome
Skye Bioscience Inc
Settore
Industria
Telefono
(858) 410-0266
Indirizzo
11250 EL CAMINO REAL, SUITE 100, SAN DIEGO
Confronta SKYE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SKYE
Skye Bioscience Inc.
|
3.10 | 12.89M | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.40 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1495 | 337.87M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
2.79 | 118.85M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
1.00 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
40.56 | 0 | 0 | 0 | 0 | 0.00 |
Skye Bioscience Inc Stock (SKYE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-28 | Iniziato | William Blair | Outperform |
| 2024-09-30 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-07-09 | Iniziato | Craig Hallum | Buy |
| 2024-05-23 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-04-12 | Iniziato | Oppenheimer | Outperform |
Mostra tutto
Skye Bioscience Inc Borsa (SKYE) Ultime notizie
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Purchased by Deutsche Bank AG - Defense World
Deutsche Bank AG Purchases 32,054 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (NASDAQ:SKYE) Shares Up 24%Still a Buy? - MarketBeat
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by BNP Paribas Financial Markets - Defense World
BNP Paribas Financial Markets Has $90,000 Stock Holdings in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Northern Trust Corp Sells 5,170 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by Northern Trust Corp - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Up 24% – Should You Buy? - Defense World
Skye Bioscience (NASDAQ:SKYE) Trading Up 24% – Here’s What Happened - Defense World
Skye Bioscience’s SWOT analysis: obesity drug stock poised for pivotal data - Investing.com Nigeria
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Sold by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $923,000 Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
3 Stocks Targeting Weight Loss Market With Cannabinoid-Based Therapies - Zacks Investment Research
Arecor CEO on Skye Bioscience partnership and the value of collaborations - Proactive financial news
Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewswire
Skye Bioscience to Participate in Upcoming Investment Conferences - GlobeNewswire Inc.
Skye Bioscience’s (SKYE) Outperform Rating Reiterated at William Blair - Defense World
Skye Bioscience (NASDAQ:SKYE) Earns Outperform Rating from William Blair - Defense World
Ensign Peak Advisors Inc Has $2.17 Million Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Protagenic and Phytanix merger prompts a stock surge - BioWorld MedTech
Skye Bioscience Establishes Partnership with Arecor Therapeutics - GuruFocus
Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews
Arecor shares jump 10% on obesity drug partnership with Skye Bioscience - Proactive financial news
Arecor partners with Skye Bioscience to improve formulation of obesity drug - Proactive financial news
Skye Bioscience Partners with Arecor Therapeutics to Enhance Nimacimab Formulation for Obesity Treatment - Nasdaq
Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab - The Manila Times
Skye Bioscience Establishes Partnership with Arecor - GlobeNewswire
New Obesity Drug Breakthrough: Skye Bioscience's Once-Weekly Treatment Gets Powerful Upgrade - Stock Titan
Skye Bioscience, Inc. (NASDAQ:SKYE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Skye Bioscience (NASDAQ:SKYE) Posts Quarterly Earnings Results, Beats Expectations By $0.03 EPS - MarketBeat
Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of “Buy” from Analysts - Defense World
Skye Bioscience, Inc. (NASDAQ:SKYE) Receives $16.60 Consensus PT from Analysts - Defense World
Brokerages Set Skye Bioscience, Inc. (NASDAQ:SKYE) Target Price at $16.60 - Defense World
Skye Bioscience Awards 100,000 Share Options at $1.82 with 4-Year Vesting Terms - Stock Titan
Skye Bioscience (SKYE) Reveals Key Findings on CB1 Inhibitors an - GuruFocus
Skye Bioscience Clinical Model Demonstrating Necessity of - GlobeNewswire
Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity - Stock Titan
Skye Bioscience, Inc. (NASDAQ:SKYE) Shares Bought by Barclays PLC - Defense World
Barclays PLC Has $198,000 Stock Position in Skye Bioscience, Inc. (NASDAQ:SKYE) - Defense World
Skye Bioscience (SKYE) Receives Adjusted Price Target from Oppen - GuruFocus
Oppenheimer cuts Skye Bioscience price target to $17 By Investing.com - Investing.com South Africa
Oppenheimer cuts Skye Bioscience price target to $17 - Investing.com
Braidwell LP Invests $2.34 Million in Skye Bioscience, Inc. (NASDAQ:SKYE) - MarketBeat
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Skye Bioscience, Inc. (SKYE) - ACCESS Newswire
Skye Bioscience Inc Azioni (SKYE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):